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Background: Little is known concerning the effect of ezetimibe for secondary prevention in post-myocardial
infarction (MI) patients. In this study, we investigated the secondary prevention effect of ezetimibe for post-MI
patients.
Methods: This study is a retrospective analysis of Assessing Lipophilic vs. hydrophilic Statin therapy for Acute MI
(ALPS-AMI study). The patients were divided into two groups: those administered a statin to control low density
lipoprotein-cholesterol (LDL-C), the ezetimibe(−) group, and those administered ezetimibe in addition to a statin
to control LDL-C, the ezetimibe(+) group. The endpoints wereMajor Adverse Cardiac and Cerebrovascular Event
(MACCE), including all-cause death, recurrence of MI, stroke, and heart failure requiring hospitalization, and
MACCE with revascularization.
Results: The ezetimibe(+) and ezetimibe(−) groups contained 113 and 337 patients, respectively. Incidences of
MACCE and MACCE with revascularization were lower in the ezetimibe(+) group than in the ezetimibe(−)
group (2.6% vs. 11.5%, p= 0.002; 23.0% vs. 36.7%, p= 0.014, respectively). Moreover, logistic regression analysis
revealed ezetimibe(+) was a signiﬁcant negative predictor of MACCE (OR 0.208, 95% CI 0.048 to 0.903, p =
0.047) and MACCE with revascularization (OR 0.463, 95% CI 0.258 to 0.831, p = 0.008). The preventive effect of
ezetimibe against MACCE was observed in both moderate- and high-intensity lipid lowering treatment groups
(0% vs. 17%; p = 0.077, 3.1% vs. 9.4%; p = 0.033).
Conclusions: In lipid-lowering therapy post-MI, ezetimibe and statin combination therapy improvedMACCE with
or without revascularization compared with statin monotherapy. These ﬁndings suggest that post-MI secondary
prevention should be more intensive.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Low-density lipoprotein cholesterol (LDL-C) is considered an impor-
tant target for the prevention of atherosclerotic events [1–3]. Insufﬁcient
control over LDL-C increases the atherosclerotic plaque burden and
worsens plaque vulnerability [4–6]. Previous ACC/AHA guidelines recom-
mended an absolute decrease in LDL-C levels below 100mg/dl, while the
current guideline recommends a 30–50% decrease ormore from baseline
levels to prevent secondary atherosclerotic events. Moreover, the new
ACC/AHA guideline recommends statins as the only agents to reduce
LDL-C and improve lipidmetabolism, and thus prognosis, for post-MI pa-
tients [7]. In many investigations, statin use was reported to improvearMedicine, Shinshu University
, Japan. Tel.: +81 263 37 3486;
.
land Ltd. This is an open access articlplaque burden and vulnerability [4–6] and the prognosis of atheroscle-
rotic disease patients. However, although in the modern era statins are
considered a necessary agent to improve atherosclerotic disease, statin
monotherapy does not sufﬁciently prevent atherosclerotic disease [8].
Strict lipid-lowering therapywith another agent combinedwith a statin
may be required to prevent secondary atherosclerotic events. Ezetimibe,
a selective Niemann–Pick C1-like protein (NPC1L1) inhibitor, employs a
different mechanism from statins to improve cholesterol metabolism by
inhibiting intestinal cholesterol absorption [9]. Many investigations
have reported favorable effects of ezetimibe for atherosclerosis [10].
Thus, we investigated the impact of combination therapywith ezetimibe
and statin for secondary prevention of MI.
2. Materials and methods
This study is a retrospective analysis of prospectively collected data
assessing lipophilic vs. hydrophilic statin therapy for acute MI (ALPS-e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Comparison of characteristics at baseline and 24 months between the ezetimibe(+) and
ezetimibe(−) groups. Baseline characteristics.
Ezetimibe(+) Ezetimibe(−) p value
n = 113 n = 337
Female sex n = 450 (%) 23 (20.3) 61 (18.1) 0.343
Age (years) 62.13 ± 11.5 67.1 ± 10.9 b0.0001
BMI (kg/m2) 24.17 ± 3.79 23.6 ± 3.7 0.303
Hypertension n = 449 (%) 55 (48.6) 146 (43.3) 0.205
Diabetes mellitus n = 450 (%) 31 (27.4) 126 (37.3) 0.034
Smoking n = 450 (%) 76 (67.2) 212 (62.9) 0.237
Familial history n = 450 (%) 31 (27.4) 67 (19.8) 0.062
Hemoglobin (g/dl) 14.56 ± 1.9 14.4 ± 2.4 0.69
Creatinine (mg/dl) 0.82 ± 0.24 0.89 ± 0.64 0.288
eGFR (ml/min/1.73 m2) 73.88 ± 17.5 71.03 ± 20.09 0.179
T-chol (mg/dl) 228 ± 39.1 194.7 ± 35.6 b0.0001
HDL-C (mg/dl) 47.1 ± 10.9 47.7 ± 11.8 0.666
LDL-C (mg/dl) 153 ± 34.2 123.6 ± 29.6 b0.0001
TG (mg/dl) 167.7 ± 142.3 126.3 ± 88.1 b0.0001
Non-HDL (mg/dl) 184 ± 40.2 148.7 ± 35.1 b0.0001
HbA1c (%) 5.79 ± 1.1 5.97 ± 1.17 0.164
STEMI 84 (74.3) 246 (72.9) 0.32
pAf n = 433 (%) 3 (2.6) 12 (3.5) 0.436
NSVT n = 433 (%) 31 (27.4) 23 (6.8) 0.003
Killip class ≥ 2 9 (7.9) 43 (12.7) 0.107
BNP (pg/ml) 101.8 ± 160.1 134.7 ± 179.9 0.125
LVEF (%) 55 ± 10.7 54.8 ± 12.2 0.87
Triple vessel disease (%) 9 (7.9) 21 (6.2) 0.296
Abbreviations. BMI: body mass index, eGFR: estimated glomerular ﬁltrated rate, T-chol:
total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipopro-
tein cholesterol, TG: triglyceride, STEMI: ST-elevated myocardial infarction, pAf: paroxys-
mal atrial ﬁbrillation, NSVT: non-sustained ventricular tachycardia, BNP: brain natriuretic
peptide, LVEF: left ventricular ejection fraction.
Table 2
Lipid parameter at 24 months and differences between values at baseline and 24months.
Ezetimibe(+) Ezetimibe(−) p value
n = 108 n = 311
24 M T-chol (mg/dl) 167.1 ± 29.5 155.2 ± 24.1 0.001
24 M HDL-C (mg/dl) 49.2 ± 11.3 49.5 ± 11.8 0.865
24 M LDL-C (mg/dl) 94.6 ± 24.7 83.7 ± 17.8 b0.0001
24 M TG (mg/dl) 163.8 ± 97.6 132.9 ± 75.7 0.004
ΔT-chol (mg/dl) −73.1 ± 36.8 −56.9 ± 31.2 b0.0001
ΔLDL-C (mg/dl) −69.8 ± 32.1 −51.7 ± 26.3 b0.0001
ΔHDL-C (mg/dl) 12.9 ± 7.1 13.8 ± 9.2 0.345
ΔTG (mg/dl) −73.1 ± 36.8 −56.9 ± 31.2 b0.0001
Abbreviations. Same as in Table 1. 24 M: 24 months.
Δ indicates the difference between values at baseline and 24 months.
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atorvastatin vs. hydrophilic pravastatin [11,12]. This study was a
prospective, randomized, open-labeled, blinded endpoint study that re-
quired patients at 20 participating sites in Nagano and Niigata prefec-
tures of Japan. The inclusion criteria included: male or female, aged
N20 years, written informed consent, and percutaneous coronary inter-
vention (PCI) to treat either ST-segment elevation or non-ST-segment
elevation acute MI done within 96 h. Exclusion criteria included
planned surgery for coronary artery bypass grafting, pregnancy, active
liver or renal disease, malignant disease, withdrawal of informed con-
sent, and serious arrhythmic events or the presence of hemodynamic
instability (hypotension, congestive heart failure, ormechanical compli-
cation following acute MI). Patients were randomly allocated to receive
10 mg of either atorvastatin or pravastatin once daily, with the treat-
ment goal to reduce the LDL-C level below 100 mg/dl. If necessary, the
dose was increased to 20 mg in one month after admission of statin. If
the treatment goal still was not achieved with statin monotherapy,
then 10 mg ezetimibe was added in one month after increasing each
statin dose up to 20 mg. Patients were enrolled from June 2008 to
December 2010 and followed for at least 24months. The studywas per-
formed in accordance with the Declaration of Helsinki ant the Good
Clinical Practice Guidelines. The protocol was approved by each partici-
pating site's ethics committee, and was registered at the University
Hospital Medical Information Network (UMIN000001521).
2.1. Patient population
According to ALP-AMI study criteria, we screened 450 patients.
The patients were divided into two groups: those administered
only a statin to control LDL-C level, the ezetimibe(−) group, and
those administered ezetimibe in addition to a statin to control LDL-C
level, the ezetimibe(+) group. The endpoints were major adverse
cardiac and cerebrovascular events (MACCE), including all-cause
death, cardiovascular death, recurrence of myocardial infarction,
stroke, and heart failure requiring hospitalization, and MACCE with
revascularization.
2.2. Guideline of lipid lowering therapy for secondary prevention of
post-myocardial infarction patient
In the 2013ACC AHAguideline on the treatment of blood cholesterol
to reduce atherosclerotic cardiovascular risk in adults, patients with a
history of clinical atherosclerotic systemic cardiovascular disease in-
cluding myocardial infarction were divided into 2 groups; patients
≤75 years old received high-intensity lipid lowering therapy, while
those N75 years old were assigned tomoderate-intensity lipid lowering
therapy. In the guideline, the target level of LDL-Cwas not set, and statin
titration was not recommended. Furthermore, statin was only the rec-
ommended agent for lipid lowering therapy, and other agents including
ezetimibe were not recommended. However, we consider that the ef-
fect of ezetimibe and statin combination therapy should be examined
in each therapy intensity group.
2.3. Statistical analysis
Continuous variables are presented as mean ± standard deviation,
and categorical variables are expressed as a number and percentage.
Continuous variables were compared using the two-sided paired
t-test, and categorical variables were compared using the chi-
square test or Fisher's exact test, as appropriate. All p values are
two-sided, and results with p b 0.05 were considered statistically
signiﬁcant. A logistic regression model was subsequently used to
analyze the incidence of MACCE and MACCE with revascularization.
As the ﬁrst step, potential predictors of MACCE and MACCE with re-
vascularization incidence were separately assessed in logistic re-
gression analyses. Then multiple logistic regression analysis wasconducted for covariates that demonstrated an association with the
incidence of MACCE and MACCE with revascularization (p ≤ 0.10).
Results are expressed as odds ratios with 95% conﬁdence intervals
(95% CI). All analyses were performed using SPSS statistical software,
version 13.0 (SPSS Inc., Chicago, Illinois).3. Results
3.1. Baseline characteristics
Baseline clinical characteristics of the ezetimibe(+) and ezetimibe(−)
groups are compared in Table 1. The ezetimibe(+) and ezetimibe(−)
groups contained 113 and 337 patients, respectively. The ezetimibe(−)
group was signiﬁcantly older than the ezetimibe(+) group (62.1 ± 11.5
vs. 67.1 ± 10.9 years, p b 0.0001). There were no signiﬁcant differences
in history of hypertension or smoking. Diabetes mellitus was observed
in 31 patients in the ezetimibe(+) group (27.4%) and 126 (37.3%) in
the ezetimibe(−) group (p = 0.034). Total cholesterol and LDL-C
Fig. 1. The difference in the lipid parameters between values of baseline and 24months after, comparison between the ezetimibe(+) and ezetimibe(−) groups. T-chol, LDL-C and TGwere
decreased signiﬁcantly in the ezetimibe group comparedwith those in the ezetimibe(−) group between values at baseline and 24months. HDL-Cwas increased in both ezetimibe(+) and
ezetimibe(−) groups, however there were no signiﬁcant differences in ΔHDL-C between the ezetimibe(+) and ezetimibe(−) groups.
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ezetimibe(−) group (228 ± 39.1 mg/dl vs. 194.7 ± 35.6 mg/dl,
p b 0.0001; 153 ± 34.2 mg/dl vs. 123.6 ± 29.6 mg/dl, p b 0.0001).
There were no signiﬁcant differences in serum creatinine level
(0.82 ± 0.24 mg/dl vs. 0.89 ± 0.64 mg/dl, p = 0.288), estimated
glomerular ﬁltration rate (73.88 ± 17.5 ml/min/1.73 m2 vs. 71.03 ±
20.1 ml/min/1.73 m2, p = 0.179), BNP (101.8 ± 160.1 pg/ml vs.
134.7 ± 179.9 pg/ml, p = 0.125), or left ventricular ejection fraction
(55 ± 10.7% vs. 54.8 ± 12.2%, p = 0.87).
Table 2 revealed lipid parameters at twenty-four months and differ-
ences between values at baseline and 24 months. At 24 months, LDL-C
and TG levels were still higher in the ezetimibe(+) group compared
with those in the ezetimibe(−) group (94.6 ± 24.7 mg/dl vs. 83.7 ±
17.8 mg/dl, p b 0.0001; 163.8 ± 97.6 mg/dl vs. 132.9 ± 75.7 mg/dl,
p = 0.004, respectively), while the difference of lipid parameters
was higher in the ezetimibe(+) group compared with that in the
ezetimibe(−) group (ΔLDL-C−69.8 ± 32.1 mg/dl vs.−51.7 ± 26.3 mg/
dl, p b 0.0001; ΔTG −73.1 ± 36.8 mg/dl vs. -56.9 ± 31.2 mg/dl, p b
0.0001) (Table 2, Fig. 1).Fig. 2. Comparison of MACCE and MACCE with revascularization between the ezetimibe(+)
revascularization was lower in the ezetimibe(+) group compared with that in the ezetimibe(−3.2. MACCE and MACCE with revascularization
The composite endpoints, incidence of MACCE and MACCE with
revascularization, were lower in the ezetimibe(+) group than the
ezetimibe(−) group (2.6% vs. 11.5%, p = 0.002; 23.0% vs. 36.7%,
p = 0.004) (Fig. 2) All-cause death and cardiovascular death were
not observed in the ezetimibe(+) group, but occurred in 24 (7.1%)
and 15 (4.4%) patients (p = 0.001 and 0.012), respectively, in the
ezetimibe(−) group. There were no signiﬁcant differences in heart fail-
ure requiring hospitalization, stroke, or any revascularization between
the two groups.3.3. Analysis according to lipid lowering therapy intensity
According to the 2013ACC/AHAguidelinepatientswere divided into
2 groups; patients ≤75 years old received high-intensity lipid lowering
therapy, while those N75 years old were assigned to moderate-
intensity lipid lowering therapy.and ezetimibe(−) groups. Among all patients, the incidence of MACCE and MACCE with
) group.
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and moderate-intensity lipid lowering therapy group included 113
patients, respectively. The incidence of MACCE was lower in the
ezetimibe(+) group compared with that in the ezetimibe(−) group
in both the high-intensity and moderate-intensity groups (0% vs. 17%,
p = 0.077, 3.1% vs. 9.4%, p = 0.033, respectively) (Fig. 3A). The inci-
dence of MACCE with revascularization was also lower in the
ezetimibe(+) group compared with that in the ezetimibe(−) group
in patients receiving both high-intensity and moderate-intensity statin
therapies (25% vs. 43.4%, p = 0.132; 22.6% vs. 34.2%, p = 0.023, respec-
tively) (Fig. 3B).
3.4. Multivariate analysis
In univariate analysis, age, serum creatinine level, and BNPwere sig-
niﬁcantly associated with the incidence of MACCE (71.1 ± 10.2 vs.Fig. 3. Comparison of MACCE andMACCE with revascularization between the ezetimibe(+
erate- and high-intensity groups, the incidence of MACCE decreased in patients administe
(−)). (B) In both the moderate-intensity group and high-intensity group, the incidence o
pared with that in the ezetimibe(−) group.65.4 ± 11.3, p = 0.002; 1.16 ± 1.44 vs. 0.84 ± 0.36, p = 0.0001;
206.1 ± 218.9 vs. 116.8 ± 167, p = 0.004) (Table 3). Serum creatinine
level and BNP were also signiﬁcantly associated with the incidence
of MACCE with revascularization (0.96 ± 0.92 vs. 0.82 ± 0.22, p =
0.018; 152.4 ± 181.1 vs. 111.9 ± 169.5, p = 0.038) (Table 4), and
female sex was a negative predictor for MACCE with revasculariza-
tion (13.1% vs. 21.6%; p = 0.017) (Table 5). Table 5 demonstrated
multivariate analysis, included p b 0.05 variables in univariate
analysis, and revealed incidence of MACCE and MACCE with revas-
cularization. BNP (OR 1.002, 95% CI 1.000 to 1.003, p = 0.036) and
ezetimibe(+) therapy (OR 0.204, 95% CI 0.047 to 0.885, p =
0.034) were associated with the incidence of MACCE (Table 5).
Moreover, multivariate analysis for MACCE with revascularization
revealed that BNP (OR 1.001, 95% CI 1.000 to 1.003, p = 0.038)
and ezetimibe(+) therapy (OR 0.445, 95% CI 0.249 to 0.795, p =
0.006) were independent risk factors. (Table 5) In the multivariate) and ezetimibe(−) groups according to statin therapy intensity. (A) In both the mod-
red ezetimibe (ezetimibe(+)) compared with that in statin monotherapy (ezetimibe
f MACCE with revascularization was also decreased in the ezetimibe(+) group com-
Table 3
Univariate analysis of predictors for the incidence of MACCE.
MACCE(+) MACCE(−) OR 95% CI p value
n 42 416
Female sex (%) 7 (16.6) 79 (18.9) 0.853 0.366–1.991 0.837
Hypertension (%) 17 (40.4) 186 (44.7) 0.837 0.439–1.597 0.628
Diabetes mellitus (%) 13 (30.9) 146 (35.0) 0.829 0.418–1.644 0.361
Familial history (%) 6 (14.2) 92 (22.1) 0.587 0.240–1.436 0.734
pAf (%) 3 (7.1) 12 (2.8) 2.622 0.708–9.710 0.147
STEMI (%) 33 (78.5) 301 (72.3) 3.728 0.873–15.912 0.062
Age (years) 71.1 ± 10.2 65.4 ± 11.3 1.049 1.017–1.082 0.002
BMI (kg/m2) 23.5 ± 3.3 23.7 ± 3.8 0.982 0.900–1.072 0.69
Hemoglobin (g/dl) 13.8 ± 2.1 14.5 ± 2.3 0.824 0.694–0.980 0.056
Creatinine 1.16 ± 1.44 0.84 ± 0.36 1.655 1.026–2.668 0.0001
BNP 206.1 ± 218.9 116.8 ± 167 1.002 1.001–1.004 0.004
HbA1c 5.73 ± 0.65 5.94 ± 1.19 0.820 0.564–1.191 0.295
Ezetimibe(+) (%) 3 (7.1) 39 (9.4) 0.208 0.063–0.688 0.004
Abbreviations. pAf: paroxysmal atrial ﬁbrillation, STEMI: ST elevated myocardial infarc-
tion, BMI: body mass index, BNP: brain natriuretic peptide, HbA1c: hemoglobin A1c.
Table 5
Multivariate analysis of predictor for the incidence of MACCE and MACCE with
revascularization.
95% CI OR p value
MACCE
Age 0.999–1.072 1.035 0.054
BNP 1.000–1.003 1.002 0.036
Creatinine 0.939–2.145 1.419 0.097
Ezetimibe(+) 0.047–0.885 0.204 0.034
MACCE with revascularization
Female sex 0.337–1.245 0.648 0.193
BNP 1.000–1.003 1.001 0.038
Creatinine 0.829–2.550 1.454 0.191
Ezetimibe(+) 0.249–0.795 0.445 0.006
Abbreviations. BNP: brain natriuretic peptide.
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both MACCE and MACCE with revascularization in this study
population.4. Discussion
In the present study, ezetimibe and statin combination therapy
decreased the incidence of all-cause death and cardiovascular death as
well as the incidence of MACCE and MACCE with revascularization in
post-MI patients.
Statins are only agent recommended for secondary prevention of
atherosclerotic events in new guidelines [7] based on their favorable ef-
fects of lowering LDL-C, increasing high-density lipoprotein cholesterol
(HDL-C) levels, and stabilizing coronary artery atherosclerotic plaques.
In recent years, it was recommended that LDL-C level should be
decreased as much as possible by lipid lowering therapy. However,
the theory has changed, and the most recent guideline does not set
target levels for LDL-C control. It is recommended only that a sufﬁcient
dose of statin should be admitted according to the desired treatment
intensity. However, the recurrence rate of MI remains high [13], and
given the high mortality of patients with recurrent MI, often due to
lost cardiac function and complicatedwith renal dysfunction, secondary
prevention should be more intensive [14]. Therefore, another approach
for lipid lowering therapy could be valuable for the secondary preven-
tion of atherosclerotic disease.
Ezetimibe is a comparatively new cholesterol-lowering drug with a
different mechanism from statins [15], and thus could provide anotherTable 4
Univariate analysis of predictor for incidence of MACCE with revascularization.
MACCE
+revascularization(+)
MACCE
+revascular
n 153 305
Female sex (%) 20 (13.1) 66 (21.6)
Hypertension (%) 61 (39.8) 142 (46.5)
Diabetes mellitus (%) 56 (36.6) 103 (33.7)
Familial history (%) 25 (16.3) 73 (23.9)
pAF (%) 6 (3.9) 9 (2.9)
STEMI (%) 115 (75.1) 219 (71.8)
Age (years) 67.5 ± 11.4 65.1 ± 11.2
BMI (kg/m2) 23.5 ± 3.1 23.8 ± 4.01
Hemoglobin (g/dl) 14.3 ± 1.9 14.5 ± 2.4
Creatinine (mg/dl) 0.96 ± 0.92 0.82 ± 0.22
BNP (pg/dl) 152.4 ± 181.1 111.9 ± 169
HbA1c (%) 5.87 ± 0.94 5.95 ± 1.25
Ezetimibe(+) (%) 26 (16.9) 87 (28.5)
Abbreviations as in Table 3.quality lipid control treatment. It reduces cholesterol by inhibiting the
absorption of LDL-C from the intestinal mucous membrane. Buchwald
et al. reported that partial ideal bypass improved the blood lipid levels
of acute MI patients and their morbidity due to coronary heart disease
[16]. Ezetimibe and statin combination therapy has also been reported
to reduce LDL-C level more than statin monotherapy [17–19]. The
balance between cholesterol absorption and synthesis was revealed to
correlate with atherosclerosis progression [20] and may be improved
by ezetimibe. In the present study, we measured campesterol-to-
lathoserol ratio, reﬂecting the balance between absorption and synthe-
sis of a cholesterol marker, in 72 patients: 17 ezetimibe(+) and 55
ezetimibe(−) and found that it decreased signiﬁcantly in the
ezetimibe(+) group (2.36± 1.01 vs. 5.58± 2.85; p b 0.001). Ezetimibe
has also demonstrated favorable effects on atherosclerotic plaques,
acting to improve plaque vulnerability by reducing plaque burden
and improving thinning of the ﬁbrous cap of plaques similar to statin
therapy [21].
In the present study, ezetimibe and statin combination therapy
improved all-cause death and cardiovascular death comparedwith stat-
in monotherapy. Lin et al. reported that post-acute coronary syndrome
patients treated with ezetimibe combined with statins had a lower risk
of re-hospitalization due to acute coronary syndrome recurrence and
revascularization than those administered statin monotherapy [22]. In
addition, the Improved Reduction of Outcomes: Vytorin Efﬁcacy Inter-
national Trial (IMPROVE-IT), the only prospective randomized trial to
compare ezetimibe with statin combination therapy and statin mono-
therapy [23], revealed a clinical mortality beneﬁt of ezetimibe and
simvastatin combination therapy in patients presenting with acute
coronary syndrome. The clinical beneﬁt of ezetimibe combined with
high-potency statin therapy in patients with renal dysfunction has
also been established: a sufﬁcient dose of simvastatin plus ezetimibeization(−)
OR 95% CI p value
0.545 0.316–0.938 0.031
0.756 0.510–1.122 0.195
1.132 0.755–1.699 0.603
0.621 0.375–1.026 0.070
1.343 0.469–3.847 0.586
1.517 0.848–2.714 0.165
1.019 1.001–1.037 0.33
0.978 0.927–1.032 0.415
0.945 0.856–1.043 0.259
1.984 0.922–4.267 0.018
.5 1.001 1.000–1.002 0.038
0.944 0.787–1.133 0.537
0.513 0.314–0.839 0.008
159S. Ebisawa et al. / IJC Heart & Vasculature 8 (2015) 154–160reduced the incidence of major atherosclerotic events in chronic kidney
disease patients compared with statin monotherapy [24].
By contrast, Pauriah et al. reported no observed mortality beneﬁt of
ezetimibe and statin combination therapy comparedwith high-potency
statin therapy in post-MI patients [25]. Several points differ between
this previous study and our study. In the previous study, criteria for
ezetimibe administration depended on the judgment of clinicians, and
the intensity of statin therapy varied across individuals in the ezetimibe
and statin combination therapy group. In the present study, ezetimibe
was added after statin administration reached a pre-established maxi-
mum dose. Statin therapy is currently themain strategy for lipid lower-
ing in the secondary prevention of atherosclerotic disease. It appears
that an appropriate strategy for ezetimibe administration is to use com-
bination therapy only after statins have been extended to a sufﬁcient
dose.
We observed a clinical beneﬁt of ezetimibe in both moderate-
intensity (≤75 years old) and high-intensity (N75 years old) therapy
groups. To the best of our knowledge, no prior investigations have
assessed the effects of ezetimibe according to lipid lowering therapy
intensity. Our results indicated that ezetimibe was effective in post-MI
patients in both intensity groups.
In the present study, the criteria for ezetimibe administration
depended on LDL-C level. Because LDL-C level tended to be higher in
younger patients, patients in the ezetimibe(+) group were younger,
andmeanBNP levelwas lower than in the ezetimibe(−) group. Howev-
er, we also observed that ezetimibe was a negative predictor for the
incidence of MACCE and MACCE with revascularization after adjusting
for diabetes mellitus, age, BNP, female sex, and serum creatinine level
(MACCE: 95%CI 0.072 to 0.803, OR0.241, p=0.021;MACCEwith revas-
cularization: 95% CI, 0.334 to 0.910, OR 0.552, p = 0.02).
5. Study limitations
This study has several limitations. The original ALPS-AMI study
focused on only 500 MI patients. This sample size limited the assess-
ment of these patients' prognosis. Levels of serum creatinine kinase,
indicating myocardial necrosis, were not recorded; thus the scale of
myocardial infarction was difﬁcult to estimate. Furthermore, adminis-
tration of ezetimibewas dependent on LDL-C level, creating an inherent
bias between the ezetimibe(+) and ezetimibe(−) groups. In addition, it
should be emphasized that the ezetimibe(+) group was small in com-
parison with the ezetimibe(−) group, which could impact our results
concerning the mortality beneﬁt of ezetimibe. Further prospective
randomized trial focused on ezetimibe is needed to establish the bene-
ﬁts of ezetimibe in this and other patient populations.
6. Conclusion
Ezetimibe and statin combination therapy improved the prognosis
of post-MI patients compared with statin monotherapy. This favorable
effect extended to both moderate- and high-intensity stain therapy
groups. Ezetimibe and statin combination therapy may improve the
mortality of post-MI patients.
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